🇺🇸 FDA
Pipeline program

NTX-001

W81XWH2010825

Phase 2 small_molecule active

Quick answer

NTX-001 for Peripheral Nerve Injuries is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Peripheral Nerve Injuries
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials